Munich Startup
BugSense

BugSense

Urinary tract infections (UTIs) are among the most common infections globally, affecting 152 million patients worldwide. Differentiated urine diagnostics, which form the basis for adequate therapy, are time-consuming, labor-intens...

Founded2026
Business ModelB2C
IndustryLife Science
This content was machine translated.

About BugSense

Urinary tract infections (UTIs) are among the most common infections globally, affecting 152 million patients worldwide. Differentiated urine diagnostics, which form the basis for adequate therapy, are time-consuming, labor-intensive, and resource-intensive. Incorrect or often unnecessary antibiotic administration prolongs treatment times, increases the risk of complications, and promotes the development of antibiotic resistance. BugSense is developing a paper-based test that is sustainable, affordable, scalable, and user-friendly. The test is designed to reliably identify UTI-causing pathogens in urine and potential antibiotic resistances. The test read-out is performed using a smartphone application and can be conducted from anywhere without requiring a laboratory or specialized personnel.

More like this

Discover relevant articles, startups, and events from the ecosystem